Nutritional Status Changes During Pediatric Acute Lymphoblastic Leukemia Treatment: A Study from a Tertiary Care

Sadia Imran1, Namrita Rai2, Malick Muhammed Sabih Masood1

  • 1Department of Pediatric Hematology & Oncology, Indus Hospital & Health Network, Karachi, Pakistan.

Insights

Malnutrition significantly impacts pediatric Acute Lymphoblastic Leukemia (ALL) patients, increasing infection risk. While weight changes during treatment, malnutrition does not significantly correlate with mortality in these children.

Area of Science:

  • Pediatric Oncology
  • Clinical Nutrition
  • Hematology

Background:

  • Acute Lymphoblastic Leukemia (ALL) is a leading pediatric cancer, with survival rates significantly lower in lower-to-middle-income countries (LMICs) compared to high-income countries (HICs).
  • Malnutrition is a critical factor influencing treatment outcomes and survival rates in pediatric ALL patients, particularly in resource-limited settings.

Purpose of the Study:

  • To investigate the association between nutritional status and morbidity and mortality in pediatric ALL patients undergoing treatment.
  • To ascertain changes in nutritional status during and after the intensive phase of ALL treatment.

Main Methods:

  • A retrospective study analyzed 332 pediatric ALL patients from May 2022 to April 2023.
  • Nutritional status was assessed using WHO weight-for-age and height-for-age for children aged 1-5 years, and BMI-for-age for those over 5.
  • Statistical analysis, including the Wilcoxon signed-rank test, was employed to evaluate changes in weight and associations with clinical outcomes.

Main Results:

  • Over one-third (38.5%) of the pediatric ALL patients were malnourished, predominantly underweight.
  • A significant decrease in patient weight was observed after the intensive treatment phase (P=.0177).
  • Malnutrition was significantly associated with increased bacterial infections (P=.01) and multiple hospital admissions (P=.004), but not with mortality (P>.05).

Conclusions:

  • Nutritional status undergoes significant changes during intensive ALL treatment.
  • Malnutrition in pediatric ALL is linked to higher rates of bacterial infections but not directly to mortality.
  • Further prospective research with extended follow-up is recommended to understand the long-term impact of nutritional status on survival in ALL patients.
Abstract

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...